Abstract
BackgroundBelimumab is approved for the treatment of systemic lupus erythematosus (SLE) in >75 countries [1]. Clinical trials and long-term extension (LTE) studies have demonstrated the consistent safety profile of belimumab...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
